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This study describes the operative management and out- 
come of 28 patients with obstructive hypertrophic cardio- 
myopathy and hemodynamically significant coronary ar- 
tery disease. Each patient underwent coronary artery 
bypass grafting and concomitant left ventricular myotomy- 
myectomy or mitral valve replacement. The mean age at 
operation was 59 years (range 42 to 74). 
Five patients (18%) died as a result of operation, four in 
the immediate postoperative period and one at 2 months 
postoperatively. Three patients died after the immediate 
postoperative period of causes unrelated to the operation. 
The mean follow-up period for the 20 currently surviving 
patients was 4.8 years (range 4 months to 10.8 years). 
Nineteen of these patients have experienced substantial 
functional improvement; all are currently asymptomatic or 
only mildly symptomatic. 
Twenty-one patients underwent cardiac catheterization 
before and after operation; each experienced relief of left 
ventricular outflow tract obstruction after operation. 
Twelve patients had a preoperative outflow gradient 250 
mm Hg (average 86 It 7) under basal conditions, which 
Operation has constituted an important component of the 
therapeutic management of severely symptomatic patients 
with obstructive hypertrophic cardiomyopathy since the first 
procedure for this condition was performed by Cleland (1) in 
1958. Experience at several centers (2-14) with left ventric- 
ular myotomy-myectomy or mitral valve replacement during 
the past 30 years indicates that most patients benefit symp- 
tomatically from relief of left ventricular outflow tract ob- 
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decreased to 3 f 1.8 mm Hg postoperatively (p < 0.001). 
Nine patients had a severe preoperative gradient only with 
a provocative maneuver (average 93 + 6 mm Hg), which 
decreased to 24 + 8 mm Hg postoperatively (p < 0.001). 
Five of the 24 patients undergoing left ventricular myoto- 
my-myectomy incurred an iatrogenic ventricular septal 
defect. This operative complication occurred primarily in 
patients with a relatively thin ventricular septum (<20 mm) 
and contributed importantly to postoperative death in two 
of the patients. 
Marked symptomatic and hemodynamic benefit can be 
achieved in patients requiring operation for obstructive 
hypertrophic cardiomyopathy and coronary artery disease. 
Operative mortality was higher than that in patients oper- 
ated on for either disease alone, in part because of an 
increased frequency of iatrogenic ventricular septal defect. 
Consequently, mitral valve replacement may be preferable 
to left ventricular myotomy-myectomy in some patients 
with obstructive hypertrophic cardiomyopathy, coronary 
artery disease and relatively thin ventricular septum. 
(J Am Co11 Cardiol1989;13:1527-33) 
struction and concomitant reduction of the elevated intra- 
ventricular systolic pressure. 
Clinical awareness and recognition of hypertrophic car- 
diomyopathy in patients of all ages has been enhanced over 
the past 15 years, largely due to the widespread application 
of diagnostic echocardiography. Consequently, increasing 
numbers of patients with both obstructive hypertrophic 
cardiomyopathy and concomitant angiographically docu- 
mented coronary artery disease are being identified ( 15-20). 
The presence of these two major cardiac diseases in a single 
patient may necessitate operative treatment for both. Short- 
term results (<2 year follow-up) for such operations have 
been previously reported (18-20) in a small number of 
patients. The present report documents the long-term clini- 
cal outcome of a large group of patients who underwent 
operation for both obstructive hypertrophic cardiomyopathy 
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and coronary artery disease. Assessment of the hemody- 
namic and functional status of these patients may serve to 
clarify the role of operative therapy in this subgroup of 
patients. 
Methods 
Selection of patients. The records of 466 patients under- 
going operation for obstructive hypertrophic cardiomyopa- 
thy at the National Heart, Lung, and Blood Institute be- 
tween 1960 and 1987 were reviewed. In each, left ventricular 
myotomy-myectorny or mitral valve replacement was per- 
formed to relieve left ventricular outflow tract obstruction. 
Twenty-eight (6%) of these patients also underwent concom- 
itant coronary artery bypass and comprise the present study 
group. 
The mean age at the time of operation was 59 years (range 
42 to 74); 17 (61%) were men and 11 were women. The 
clinical condition of each patient was evaluated as of January 
1, 1988. The mean follow-up period for those 23 patients who 
were discharged from the hospital after operation was 4.8 
years (range 4 months to 10.8 years). 
Patient characteristics. Each of the 28 patients was ini- 
tially referred for evaluation and treatment of hypertrophic 
cardiomyopathy. All met the following criteria for the diag- 
nosis of the obstructive form of hypertrophic cardiomyopa- 
thy (21): 1) echocardiographic demonstration of asymmetric 
hypertrophy of the ventricular septum and a nondilated left 
ventricle; 2) obstruction to left ventricular outflow resulting 
from marked systolic anterior motion of the mitral valve; and 
3) absence of an associated cardiac or systemic disease 
capable of producing left ventricular hypertrophy of the 
magnitude identified in that patient. Eleven patients (39%) 
had mild systemic hypertension (systolic blood pressure 140 
to 170 mm Hg or diastolic pressure 90 to 100 mm Hg, or 
both) that was documented by history or physical examina- 
tion. In each, hypertension had been well controlled by drug 
therapy. During the course of diagnostic evaluation, signifi- 
cant atherosclerotic narrowing (>50% of luminal diameter) 
of one or more extramural coronary arteries was docu- 
mented by coronary arteriography in each patient. 
The study patients were recommended for operative 
treatment based on the following: 1) severe cardiac symp- 
toms and functional limitation (New York Heart Association 
functional class III or IV); 2) left ventricular outflow tract 
gradient of 250 mm Hg under basal conditions or with 
provocative interventions (Valsalva maneuver, amyl nitrite 
inhalation or isoproterenol infusion); and 3) angiographically 
significant coronary artery disease, as previously defined. 
Left ventricular myotomy-myectomy is the preferred 
operative procedure for patients with hypertrophic cardio- 
myopathy at this institution and was performed in 24 of the 
28 study patients. The remaining four patients underwent 
mitral valve replacement because the basal ventricular sep- 
tum was relatively thin (15 to 21 mm) and the risk of 
incurring a ventricular septal defect by resection of septal 
muscle was judged by the surgeon to be unacceptably high. 
Operative Techniques 
Ventricular septal myotomy-myectomy. The operative 
technique was that described by Morrow (22). Briefly, the 
operation is performed through a vertical aortotomy; a bar of 
muscle is excised from the basal portion of the anterior 
septum creating a rectangular trough 1 cm wide, 1 cm deep, 
4 cm in length and extending from just below the aortic 
anulus to a point distal to the region of systolic mitral 
valve-septal contact. This results in enlargement of the 
cross-sectional area of the left ventricular outflow tract. The 
average mass of resected septal muscle in 17 of the 24 
patients was 1.9 g (range 0.8 to 4.3). 
Mitral valve replacement. This was performed in four 
patients utilizing standard techniques (23). The small left 
ventricular cavity of patients with obstructive hypertrophic 
cardiomyopathy required implantation of a low profile tilt- 
ing-disc prosthesis (Bjork-Shiley model MBRP; two were 23 
mm and two were 2.5 mm). 
Coronary artery bypass grafting. Bypass grafts were con- 
structed with reversed saphenous veins in all 28 patients. 
Myocardial revascularization was performed after myoto- 
my-myectomy. Coronary bypass grafts were constructed 
before valve implantation in all four patients who underwent 
mitral valve replacement. 
Eleven patients received a single bypass graft, 10 re- 
ceived two grafts, 6 received three grafts and 1 patient 
received four grafts. The left anterior descending coronary 
artery was most frequently bypassed artery (in 18 patients); 
other bypassed arteries were the right coronary artery (in 
14), obtuse marginal branch (in 13) diagonal branch (in 4) 
and posterior descending artery (in 2). Five of these 53 
arteries required endarterectomy before bypass grafting. Of 
the 28 study patients, 21 underwent bypass of all signifi- 
cantly diseased arteries and were therefore considered to 
have had complete myocardial revascularization. In the 
other seven patients, it was not possible to bypass one 
diseased artery because of the small caliber of the vessel; 
these patients were considered to have had incomplete 
revascularization. 
Myocardial protection. Two methods of myocardial pro- 
tection were used. Before July 1983, left ventricular myoto- 
my-myectomy was performed with 30°C total body hypo- 
thermia and ischemic arrest (18 patients); intermittent 
coronary perfusion with cold crystalloid cardioplegic solu- 
tion was employed during myocardial revascularization. 
Since July 1983, induction of cardioplegic arrest has been 
carried out before myotomy-myectomy or mitral valve re- 
placement with the use of a cold, oxygenated, hyperkalemic 
crystalloid solution (10 patients). The cardioplegic solution 
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Figure 1. Flow diagram showing clinical outcome in 28 patients 
undergoing coronary artery bypass grafting and either left ventric- 
ular myotomy-myectomy or mitral valve replacement. Ca = cancer; 
CHF = congestive heart failure: CVA = cerebrovascular accident. 
was administered every 20 min throughout the operative 
procedure. In addition, topical myocardial cooling was car- 
ried out with iced slush. The mean duration of aortic cross 
clamping was 92 min (range 34 to 2 11). 
Echocardiography. Two-dimensional echocardiograms 
were performed with either an Advanced Technology Lab- 
oratory Mark 500 or a Diasonics CV-400 real-time mechan- 
ical sector scanner and a 2.25 MHz transducer. M-mode 
echocardiograms were recorded with a dedicated Irex Sys- 
tem III ultrasound unit or derived from two-dimensional 
images under direct anatomic visualization. Left ventricular 
dimensions were measured in accordance with the recom- 
mendations of the American Society of Echocardiography 
(24). 
Statistical methods. Data are expressed as mean values 2 
standard error. Differences between group means were 
analyzed using the unpaired Student’s I test. Nonparametric 
data were analyzed using the chi-square test. 
Results 
Mortality (Fig. 1). Operative mortality. Four (14%) of the 
28 patients died in the immediate postoperative period (530 
days) because of low cardiac output (two patients), iatroge- 
nit ventricular septal defect (one patient) and mediastinitis 
(one patient). One other patient died 2 months postopera- 
tively of left ventricular failure that occurred immediately 
after patch closure of a ventricular septal defect created 
during the initial operation. Hence, 5 (18%) of the 28 patients 
PREOP POSTOP 
Figure 2. Peak systolic left ventricular outflow tract (LVOT) gradi- 
ent measured preoperatively (PREOP) and postoperatively 
(POSTOP) under basal conditions in the 12 patients with hypertro- 
phic cardiomyopathy and coronary artery disease who had a pre- 
operative basal gradient 250 mm Hg. = mean value t standard 
error. 
died as a consequence of operation. These five patients did 
not differ from those who survived operation with respect to 
the method of myocardial preservation or the duration of 
aortic cross clamping. The mortality rate was 16% (3 of 19) 
in patients undergoing operation with ischemic arrest and 
22% (2 of 9) in patients without ischemic arrest. Mean 
cross-clamp time was 116 min in patients who died as a result 
of operation and 103 min in those who survived. 
Late rnortuliry. One patient who had a mitral valve 
replacement died after a cerebrovascular accident 4 months 
after operation. A second patient died from lung cancer 2 
years after operation and a third from progressive congestive 
heart failure 7 years after operation. 
Echocardiography. Preoperative echocardiograms were 
available for analysis in 27 of the 28 patients. Ventricular 
septal thickness was measured at end-diastole at mitral valve 
level where systolic anterior motion was evident. Mean 
septal thickness was 21 mm (range 15 to 38); it was ~18 mm 
in four patients and ~30 mm in three. The mean left 
ventricular posterior wall thickness was 12 mm (range 8 to 
18); the mean left ventricular transverse end-diastolic dimen- 
sion was 42 mm (range 34 to 52). 
Hemodynamics (Fig. 2 and 3). Complete preoperative and 
postoperative cardiac catheterization was performed in 21 
patients. The mean time interval between operation and 
postoperative catheterization was 6.8 months. In I2 of the 21 
patients, the preoperative left ventricular outflow tract gra- 
dient under basal conditions was ~50 mm Hg (mean 86 t 7; 
range 52 to 145). The postoperative basal gradient in these 
patients (Fig. 2) was 3 t 1.8 mm Hg (range 0 to 20; p < 
0.001). 
Nine of the 21 patients had a gradient ~50 mm Hg under 
basal conditions. but a gradient 250 mm Hg with provoca- 
tive interventions. The mean provokable gradient was 93 2 
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Figure 3. Peak systolic left ventricular outflow tract (LVOT) gradi- 
ent measured preoperatively and postoperatively with provocative 
interventions in nine patients with hypertrophic cardiomyopathy 
and coronary artery disease who had a preoperative basal gradient 
<50 mm Hg. 
6 mm Hg (range 68 to 120) preoperatively and 24 + 8 mm Hg 
(range 0 to 84; p < 0.001) postoperatively (Fig. 3). 
Left ventricdav end-diastolic pressure was 15 ? 1 mm Hg 
(range 4 to 24) preoperatively and 11 ? 1 mm Hg (range 4 to 
26) postoperatively. Of the 11 patients who had a preopera- 
tive left ventricular end-diastolic pressure 215 mm Hg, 8 
showed a reduction to normal values (~15) after operation 
(19 ? 1 to 12 ? 2 mm Hg; p < 0.03). 
Graft patency. A total of 39 coronary bypass grafts had 
been constructed in the 21 patients who underwent postop- 
erative coronary arteriography. Of these 39 grafts, 27 (69%) 
were shown to be patent, including 10 of 14 to the left 
anterior descending artery, 7 of 11 to the obtuse marginal 
branch, 6 of 10 to the right coronary artery, 2 of 2 to the 
diagonal branch and 2 of 2 to the posterior descending 
artery. Four patients studied had undergone coronary end- 
arterectomy in addition to bypass grafting; grafts were 
patent to three of the four arteries in which endarterectomy 
was performed. 
Symptomatic results and outcome (Fig. 4). Preoperative. 
Each of the 28 patients had severe functional limitation due 
in large measure to exertional dyspnea and fatigue; 21 
Figure 4. Preoperative (Preop), short-term postoperative (Postop) (6 
months) and long-term postoperative (mean 4.8 years) New York 
Heart Association functional class (NYHA) in 28 patients with ob- 
structive hypertrophic cardiomyopathy and coronary artery disease. 
I 
Pre0p Short-term Long-term 
Postop Postop 
patients were in functional class III and 7 were in class IV. 
Chest pain was present in each of the 28 patients and was 
judged to be moderate or severe in 27; this pain was typical 
of angina pectoris in 15 and atypical in the other 13 patients. 
Recurrent syncopal episodes occurred in five patients. 
Short-term follow-up. Six months after operation, 22 of 
the 28 patients were alive. Twenty of these had improved at 
least one functional class compared with their preoperative 
condition, including 19 patients who were asymptomatic or 
had only mild symptoms. In the remaining two patients there 
was little or no functional improvement after operation, and 
both remained in functional class III. The lack of improve- 
ment in these latter patients appeared to be due to an 
iatrogenic ventricular septal defect in one and to occlusion of 
the single coronary bypass graft constructed in the other. 
Both patients became asymptomatic after reoperation (patch 
repair of septal defect and coronary bypass grafting, respec- 
tively). All patients described improvement in the severity of 
their chest pain, including 15 with complete relief. This 
improvement in chest pain occurred even though 10 of these 
patients had occlusion of one or two bypass grafts demon- 
strated by the postoperative catheterization. 
Long-term follow-up. At most recent follow-up, 20 pa- 
tients were alive, 19 of whom were asymptomatic or only 
mildly symptomatic (functional class I or II). One patient’s 
condition deteriorated from class II, 6 months after opera- 
tion to class III at long-term follow-up. Seventeen (85%) of 
the 20 patients had minimal or no chest pain, whereas three 
experienced recurrence of angina. The four patients with 
syncope before operation did not experience this symptom 
after operation. 
Complications. Ventricular septal perforation occurred 
as a consequence of the resection of septal muscle in 5 (21%) 
of the 24 patients who underwent myotomy-myectomy. In 
one patient, the ventricular septal defect was detected infra- 
operatively and repaired with a Teflon patch. This patient 
died on the 2nd postoperative day; disruption of the repair 
and a persistent septal defect was identified at necropsy. In 
the four other patients, the ventricular septal defect was 
detected after operation. Pulmonary to systemic flow ratio 
was measured at cardiac catheterization and ranged from 
2.0: 1 to 3.4: 1. In two of these four patients the ventricular 
septal defect was detected early after operation (2 days and 
12 days, respectively) when clinical deterioration occurred 
and a holosystolic murmur was heard. Both patients under- 
went patch repair of the defect shortly thereafter; one had a 
1.2 cm defect and died the day after repair and the other was 
found to have a large defect surrounded by an area of 
necrosis. This latter patient experienced marked sympto- 
matic and hemodynamic improvement after repair. In the 
two remaining patients, the ventricular septal defect was first 
recognized at the 6 month postoperative catheterization. 
Patch repair of a 1.5 cm defect was performed in one of these 
patients who subsequently showed marked clinical improve- 
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ment. The other patient was asymptomatic and the septal 
defect was not closed. 
Preoperative echocardiographic data ti’ere available in 
four offive patients who had an iatrogenic ventricular septal 
defect. The basal septal thickness was significantly less in 
these 4 patients (mean 18.5 mm; range 15 to 22) than in the 
19 who did not incur this complication (mean 23.1 mm: range 
17 to 38; p < 0.05). In those patients who underwent mitral 
valve replacement, septal thickness was similar to that in 
those patients who incurred a ventricular septal defect after 
myotomy-myectomy (mean 18.0 versus 18.5 mm). 
There did not appear to he a relation between occurrence 
of ventricular septal defect and either distribution qf coro- 
nary artery stenosis or completeness of myocardial revascu- 
larization. Only 2 (40%) of the 5 patients with a septal defect 
had significant stenosis of the proximal left anterior descend- 
ing coronary artery whereas 14 (73%) of 19 patients without 
a septal defect had stenosis of this artery. Myocardial 
revascularization was considered to be incomplete in 1 (20%) 
of the 5 patients with a septal defect and in 6 (32%) of 19 
patients without a septal defect. 
Complete heart block necessitating implantation oj’ a 
permanent pacemaker appeared postoperatively in 2 of the 
24 patients who underwent left ventricular myotomy- 
myectomy. Heart block resulted from the resection of septal 
muscle in one and appeared after patch repair of a ventric- 
ular septal defect (performed I month after myotomy- 
myectomy) in the other. Preoperatively, neither patient had 
right bundle branch block or other conduction defects. 
Discussion 
The results of the present study show that important 
long-term symptomatic benefits can be achieved in patients 
with obstructive hypertrophic cardiomyopathy and coronary 
artery disease undergoing concomitant operation for both 
conditions. The 28 patients studied comprise the largest 
reported series of patients treated operatively for both 
diseases simultaneously. Twenty of the 28 patients survived 
the overall follow-up period (mean 4.8 years; maximum 11 
years) and 95% of these patients showed substantial and 
persistent improvement in symptoms and functional capac- 
ity. 
Results of operation. Operation for obstructive hypertro- 
phic cardiomyopathy (left ventricular myotomy-myectomy 
or mitral valve replacement) was undertaken to relieve 
dynamic obstruction to left ventricular outflow. Hemody- 
namic results after operation in these patients are similar to 
those previously reported for patients with obstructive hy- 
pertrophic cardiomyopathy unassociated with other cardiac 
diseases (I-14). After operation, each patient had complete 
or substantial reduction of the basal outflow tract gradient to 
520 mm Hg. Almost 90% of patients operated on primarily 
for relief of provokable obstruction (with no or small gradi- 
ent under basal conditions) had a provokable gradient ~40 
mm Hg after operation. In addition, about two-thirds of all 
patients who had elevated left ventricular end-diastolic pres- 
sure preoperatively had a normal value after operation. 
It is dificult to assess the relative contributions qf hyper- 
trophic cardiomyopathy and coronary artery disease to the 
symptoms described by patients in whom these two diseases 
coexist. This is due, in large part, to the complex and often 
overlapping pathophysiologic processes involved and the 
different mechanisms by which myocardial ischemia occurs 
in these two diseases (25-27). Consequently, it is also 
difficult to assess the relative contributions made by the 
relief of left ventricular outflow obstruction and myocardial 
revascularization to the symptomatic and functional im- 
provement reported by our patients after operation. Never- 
theless, given the serious potential consequences of either 
unrelieved outflow obstruction or of unrelieved hemodynam- 
ically significant coronary artery stenosis, it would appear 
advisable to treat both diseases operatively at the same time. 
Operative complications. Despite the favorable symptom- 
atic and hemodynamic results obtained in the majority of our 
patients. the mortality and morbidity directly related to 
combined myotomy-myectomy and bypass grafting were 
somewhat greater than those previously reported in patients 
undergoing operation for either condition alone (11.27-29). 
The operative mortality for coronary artery bypass grafting 
at this institution (including those patients with impaired left 
ventricular function) has been 2.5%. whereas that for left 
ventricular myotomy-myectomy has been 2.7% during the 
same time period as the present study. We do not believe 
that there is reason to implicate the technique of myocardial 
preservation during operation for the mortality experienced 
in the present study group; for example, the mean aortic 
cross-clamp time of 92 min was not excessive for this 
combined procedure. In addition, the mortality rate when 
myotomy-myectomy was performed with ischemic arrest 
before 1983 did not differ from that when the technique of 
myocardial protection was modified to avoid arrest after 
1983. 
Ventricular septal defect. This complication occurred in 5 
of the 24 patients undergoing left ventricular myotomy- 
myectomy and was the cause of death in 3 of these patients. 
This frequency of septal defect far exceeds the 4% incidence 
previously reported (10) in a series of patients undergoing 
only myotomy-myectomy (without myocardial revascular- 
ization). There are several possible explanations for the 
increased occurrence of ventricular septal defect in the 
present study group. Resection of muscle from the ventric- 
ular septum during myotomy-myectomy obviously poses a 
greater risk when septal thickness is only mildly increased 
(i.e., 15 to 19 mm) than when the septal thickness is 220 
mm. Indeed, those patients who incurred a ventricular septal 
defect had a significantly thinner septum before operation 
than did those patients without a septal defect. Neverthe- 
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less, about one-third of our patients without a ventricular 
septal defect had septal thickness 419 mm, suggesting that 
other factors may be important in determining if a ventricu- 
lar septal defect will result from operation. In this regard, 
one potential factor is septal ischemia. This could result from 
extramural coronary artery stenoses or the small artery 
abnormalities that are common in patients with hypertrophic 
cardiomyopathy (27). The presence of septal ischemia could 
alter tissue consistency and cause the septal myocardium to 
be less firm, thereby predisposing it to perforation. 
Role of mitral valve replacement. Left ventricular myot- 
omy-myectomy remains the procedure of choice in the 
majority of patients with obstructive hypertrophic cardiomy- 
opathy requiring operation. The data presented here, how- 
ever, suggest that mitral valve replacement might be a 
preferable operation in certain patients with obstructive 
hypertrophic cardiomyopathy and coronary artery disease. 
Mitral valve replacement eliminates the risk of septal perfo- 
ration associated with myotomy-myectomy while providing 
relief of left ventricular outflow tract obstruction as effec- 
tively as myotomy-myectomy (3,13). Indeed, four of our 
patients, each of whom had a relatively thin ventricular 
septum, underwent mitral valve replacement with such 
consideration in mind. The long-term outcome of patients 
with hypertrophic cardiomyopathy after mitral valve re- 
placement is not certain, although short-term data (30) would 
suggest that most patients experience symptomatic and 
hemodynamic improvement. 
The risks of mitral valve replacement in patients with 
hypertrophic cardiomyopathy are those that are character- 
istic of mechanical prosthesis implantation in general; these 
include mechanical dysfunction, thromboembolism and 
complications associated with anticoagulant therapy. The 
risk of mitral valve replacement and concomitant myocardial 
revascularization in patients with hypertrophic cardiomyop- 
athy should not, however, be equated with the relatively 
high risk of this procedure in patients with coronary artery 
disease and coexisting mitral regurgitation (31). The latter 
patients generally have poor left ventricular function, which 
is largely responsible for operative mortality; in contrast, 
patients with obstructive hypertrophic cardiomyopathy usu- 
ally have a hyperdynamic left ventricle. 
Conclusions. Marked hemodynamic benefit and long- 
term symptomatic improvement can be achieved in most 
patients with coexistent coronary artery disease and ob- 
structive hypertrophic cardiomyopathy who undergo opera- 
tion for both conditions at the same time. Combined left 
ventricular myotomy-myectomy and coronary artery bypass 
grafting was associated with greater morbidity and mortality 
than those reported after either operation alone. These 
findings warrant consideration of mitral valve replacement 
as an operative alternative to myotomy-myectomy in pa- 
tients with both coronary artery disease and obstructive 
hypertrophic cardiomyopathy. 
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